Company news

Aclaris Therapeutics, Inc. news in 2021

Aclaris Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

December 26, 2021

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

December 2, 2021

Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

November 17, 2021

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

November 2, 2021

Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

November 1, 2021

Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

August 26, 2021

Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

August 4, 2021

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021

July 7, 2021

Aclaris Announces Pricing of Public Offering of Common Stock

June 8, 2021

Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

June 7, 2021

Aclaris Announces Proposed Public Offering of Common Stock

June 7, 2021

Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

May 16, 2021

Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update

May 6, 2021

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

March 14, 2021

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

February 24, 2021

Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

February 9, 2021

Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

January 18, 2021

Decks in 2021